ProCE Banner Activity

An Expert’s Guide to ASCO 2022: Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Read expert highlights of key studies being presented at the upcoming 2022 ASCO Annual Meeting. CCO’s Independent Conference Coverage will include all the information you need to understand and integrate the latest oncology data into your clinical practice.

Released: June 01, 2022

Share

Faculty

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Christopher H. Lieu

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Stephen V. Liu

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Zofia Piotrowska

Zofia Piotrowska, MD, MHS

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Hussein Tawbi

Hussein Tawbi, MD, PhD

Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Seagen and Genmab

Faculty Disclosure

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD, has disclosed that she has received consulting fees from BluePath Solutions, Iovance, Nanobiotix, Novartis, Pfizer, and Shanghai Jo’Ann Medical Technology.

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Bristol-Myers Squibb, Constellation, Epizyme, Genmab, Kura, Kymera, MorphoSys, Nurix, Roche, Seattle Genetics, TG Therapeutics, Verastem, X4.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Christopher H. Lieu, MD, has disclosed that he has received consulting fees from Natera and funds for research support from Merck.

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Stephen Liu, MD: consultant/advisor: AstraZeneca, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz, Merck, Merus, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher (paid to institution): Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics; data and safety monitoring board: Candel Therapeutics.

Zofia Piotrowska, MD, MHS

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Zofia Piotrowska, MD, MHS, has disclosed that she has received consultant/advisor/speaker fees from Blueprint, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, and Takeda and funds for research support paid to her institution from AbbVie, AstraZeneca, Blueprint, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, and Tesaro/GSK.

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna Shroff, MD, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, CAMI, Clovis, Genentech, Incyte, Servier, QED, and Zymeworks and funds for research support from Bayer, Bristol-Myers Squibb, Exelixis, IMV, Loxo, Merck, Novocure, Nucana, Pieris, QED, Rafael, Seagen, and Taiho.

Hussein Tawbi, MD, PhD

Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein Tawbi, MD, PhD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Eisai, Genentech/Roche, Iovance, Karyopharm, Merck, Novartis, and Pfizer and funds for research support (paid to his institution) from Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, and Novartis.

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie/Genentech, Astellas/Jazz, Bristol-Myers Squibb/Celgene/Kite, Gilead Sciences, GlaxoSmithKline, Kura Oncology, Mana, Novartis, Pfizer, Rafael, Stemline, and Takeda and fees for non-CME/CE services from Dava Oncology, Kura Oncology, Pfizer, and Stemline.